神奇製藥(600613.SH)2021年度預盈6000萬-7200萬元 同比扭虧為盈
格隆匯1月21日丨神奇製藥(600613.SH)公佈,預計公司2021年度實現歸屬於上市公司股東的淨利潤與上年同期相比,將扭虧為盈,預計實現淨利潤6000萬元至7200萬元;預計2021年度扣除非經常性損益事項後,歸屬於上市公司股東的淨利潤為3000萬元至4200萬元。
報吿期內,國內新冠肺炎疫情明顯緩解,公司相關產品銷售逐步恢復;同時,公司積極優化營銷組織結構,推進主要產品銷售提升。2021年度公司主營業務收入預計增長4.92億元左右,同比預計增長 27%,帶動公司利潤的增長。
其他影響:1.公司2021年度計提資產減值損失同比大幅減少。公司2020年度計提商譽減值損失1.62億元,而本年度未發生商譽減值損失。
2.公司2021年度,處置轉讓原下屬公司貴州神奇康萊大藥房連鎖有限公司、吉林神奇康正醫藥有限公司的股權,產生非經常性的投資收益2706萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.